Clinical trials: Geographic Atrophy of the Macula
Age-Related Macular Degeneration, Geographic Atrophy
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
To conduct a precision study to assess the microperimetry function of the Spectral OCT/SLO. The study will assess variability across measurements taken by three different operator-device configuration across clinical sites…
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema
- Trial name
- NCT01692938
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Optos, PLC
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related…
- Trial name
- DRAGON (NCT01775124)
- Testing
- Ranibizumab
- Where
- 23 sites in China
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
The purpose of this study was to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received…
- Trial name
- FALCON (NCT04679935)
- Testing
- Brolucizumab
- Where
- 19 sites in Germany, Switzerland
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth…
- Trial name
- TALON (NCT04005352)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 118 sites in United States, Argentina and 18 more
- Volunteers
- 734 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration, Cognition Disorders
The Zeaxanthin and Visual Function Study
To evaluate if supplementation of zeaxanthin (with or without Lutein) is beneficial to patients with early and moderate Atrophic Age Related Macular Degeneration.
- Trial name
- ZVF (NCT00564902)
- Testing
- 3R 3'R Zeaxanthin, Lutein, Lutein and Zeaxanthin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Chrysantis, Inc.
Neovascular Age-related Macular Degeneration
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
The purpose of this extension study was to evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control-regimen for treatment of patients with neovascular age-related macular degeneration who have completed the…
- Trial name
- TALON Ext (NCT04597632)
- Testing
- brolucizumab
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
AMD (Age Related Macular Degeneration) is the leading cause of severe visual loss and blindness registration in the UK . It is a disease which affects the retina (the nerve and blood vessel network at the back of the eye…
- Trial name
- SAFARI (NCT02161575)
- Testing
- Ranibizumab
- Where
- 28 sites in Germany, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in participants with atrophic macular degeneration.
- Trial name
- NCT00447954
- Testing
- High Dose NT-501 implant, Low Dose NT-501 implant
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- Neurotech Pharmaceuticals
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals